MYGN Q1 2020 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$454M

Q1 2020 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$164M-24.3% YoY

Gross Profit

$114M69.5% margin

Operating Income

-$134M-81.5% margin

Net Income

-$115M-70.2% margin

EPS (Diluted)

$-1.55

QoQ Revenue Growth

-15.9%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$14M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$480M

Stockholders' Equity

$967M

Cash & Equivalents

$121M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$164M	$217M	-24.3%
Gross Profit	$114M	$168M	-32.2%
Operating Income	-$134M	$6M	-2366.1%
Net Income	-$115M	$7M	-1769.6%

Revenue Segments

Diagnostics

$151M92%

All Other Segments

$14M8%

Geographic Segments

UNITED STATES

$153M93%

Non Us

$11M7%